AbCheck discovers and optimizes human antibodies leveraging several proprietary platforms using both in vitro and in vivo technologies. We use phage/yeast display libraries (AbSieveTM), mass humanization and antibody optimization (AbAccelTM) to provide high quality leads. Our conceptually distinct approaches allow for broadly accessible sequence diversity and exclusivity that can be combined with any antibody design through our unique screening and optimization process. We offer a variety of business models, including deals without royalties and have proven our capabilities in multiple partnerships throughout the US and Europe. AbCheck is a wholly owned subsidiary of Affimed GmbH.